Pharmafile Logo

Apodi Ltd

Established in 2006 by a group of highly experienced outsourcing business specialists, Apodi provides comprehensive outsourcing solutions to pharmaceutical and healthcare businesses and organisations. We recognise that the business environment for these industry sectors is changing and that there is a need for highly professional, tailored outsourcing services offering a rapid, effective response and delivering the best ROI. Through commercial insight, market intelligence and highly motivated people, Apodi helps our clients achieve improved outcomes and performance. Over the years we have worked hard to break the traditional model with a focus on the changing NHS environment and the challenge we all face to improve patient outcomes.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

M3 (EU)

M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors with over 6 million members across M3-owned networks and an…

View Profile

Company Details

One St Peters Road, Maidenhead, Berks, SL6 7QU, United Kingdom
+44 (0)1628 500 890

 Latest Content from PMHub 

Pharma need to keep their ‘pull & push’ separate from their ‘inbound & outbound’

Is your pharma brand using the marketing terms ‘pull & push’ correctly?

A man walks into a surgery: The role of storytelling in pharma marketing

Communicating through stories can make your brand messages more meaningful, memorable and persuasive

Embracing the demands of the empowered ‘consumer-savvy’ patient by Ann Generlich

Our access to information, which is now constantly at our fingertips and the explosion of new technologies has shifted the buying power to increasingly ‘consumer-savvy’ patients. These are patients who choose...

The Art of Agile Marketing

The industry knows that it needs become more responsive to its stakeholders. An agile approach – which quickly improves results through a process of rapid market feedback and response –...

Could ketamine be the next big thing in depression?

Account Executive Will Frostick discusses the established treatment model for depression and its limitations, as well as a new entrant poised to revolutionise the field – ketamine.

Attracting doctors to low-demand specialties: A role for industry?

 One of the major problems that healthcare systems around the world face is a paucity of medically qualified staff entering particular specialties and subspecialties. This can be due to a...

Men vs Women in emerging markets

Our latest interactive infographic compares male vs female health characteristics in the BRIC emerging marketS

South Korea: The next global player?

In this paper, we will explore some of the key trends and outlooks for South Korea in more detail, including what lies behind its presence at the extremes of two...

20 questions: Round 4

As it's our 20th year anniversary, we invited our employees to play our version of 20 questions - this month "What’s been the funniest thing to happen to you whilst you’ve...

Will gene therapies finally be commercially viable to pharma?

Our latest Free Thinking white paper explores the science behind the idea of gene therapy and takes a look at some of the core challenges medical researchers have faced when...